Welcome to our dedicated page for Avita Medical news (Ticker: RCEL), a resource for investors and traders seeking the latest updates and insights on Avita Medical stock.
News and updates on AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) focus on its role as a therapeutic acute wound care company centered on the RECELL System and related wound care technologies. Company news frequently highlights developments in thermal burn and trauma treatment, clinical evidence for its products, and regulatory milestones in key markets.
Investors following RCEL news can expect coverage of financial results, revenue updates, and capital structure actions such as credit agreements and equity placements, as disclosed in Form 8-K filings and press releases. AVITA Medical regularly reports quarterly and annual financial performance, adjustments to revenue outlook, and steps taken to align operating expenses with its growth priorities.
News flow also includes clinical and scientific updates. AVITA Medical has reported data presentations at medical conferences, including systematic reviews of peer-reviewed literature and real-world registry analyses supporting the RECELL System in acute wound treatment. These items describe outcomes such as reduced donor site burden, faster healing, shorter hospital stays, and favorable economic impact in burn care.
Regulatory and market access developments are another recurring theme. The company has announced CE Mark approval for RECELL GO under the EU Medical Device Regulation, regulatory clearances for RECELL in Europe, Australia, and Japan, and support from Australia’s Medical Services Advisory Committee for the use of autologous skin cell suspension prepared with RECELL in severe burns. Corporate governance updates, such as board appointments and executive transitions, are also disclosed through AVITA Medical’s news releases.
For readers tracking RCEL, this news stream provides insight into the company’s clinical progress, regulatory status, financial performance, and leadership changes, all of which shape its position in the acute wound care and medical device landscape.
AVITA Medical (NASDAQ: RCEL) reported preliminary results and a 2026 outlook ahead of its J.P. Morgan presentation on Jan 14, 2026 at 5:15 p.m. PT. Q4 2025 revenue ~ $17.6M vs $18.4M a year earlier; FY 2025 revenue ~ $71.6M, up ~11% from $64.3M in 2024. The company secured a new five-year credit facility with Perceptive Advisors for up to $60M (initial $50M funded, $10M accordion available).
AVITA provided 2026 revenue guidance of $80–$85M (≈12%–19% growth) and disclosed TTM revenue covenants of $68.5M for Q1-2026 and $73M for FY2026, implying a required $15.4M revenue in Q1 2026. Clinical updates: Cohealyx-I fully enrolled and PermeaDerm-I >75% enrolled; data expected later in 2026.
AVITA Medical (NASDAQ: RCEL) announced board changes on January 5, 2026: Joe Woody was appointed as a non-executive director and Lou Panaccio retired after serving as Chairman from July 2014 to August 2025. The company is led by Interim CEO Cary Vance.
Mr. Woody brings more than two decades of medical-technology leadership, including serving as CEO of Avanos Medical from 2017 to 2024, prior service as President and CEO of Acelity, and over a decade on the AdvaMed board.
AVITA Medical (NASDAQ: RCEL) announced that CEO Cary Vance will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 at 5:15 p.m. PT.
A live audio webcast will be available via the company's Investor Relations Events & Presentations page and a replay will be posted after the presentation.
AVITA Medical (NASDAQ: RCEL) will present at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 8:30 a.m. EST. Management will be available for one-on-one investor meetings at the conference for registered attendees.
A live audio webcast of the presentation will be accessible under the Events & Presentations section of AVITA Medical's investor website at https://ir.avitamedical.com/events-and-presentations, and a replay will be available after the event.
AVITA Medical (NASDAQ: RCEL) will host an investor webinar briefing on November 12, 2025 at 2:00 p.m. PT (November 13, 2025 at 9:00 a.m. AEDT).
Interim CEO Cary Vance and CFO David O’Toole will review financial and business results from the company’s recent Q3 2025 earnings webcast and hold a live Q&A. Shareholders and prospective investors may register to submit questions in advance. A replay will be available on AVITA Medical’s investor website after the presentation.
AVITA Medical (NASDAQ: RCEL) reported Q3 2025 results for the quarter ended September 30, 2025. Commercial revenue was $17.1M, down 13% year-over-year. Operating expenses fell 24% to $23.0M, and net loss improved to $13.2M, or $0.46 per share, from $16.2M a year earlier. Cash, cash equivalents, and marketable securities totaled $23.3M at quarter end after a $13.8M private placement.
Key developments: RECELL GO received CE Mark under the EU MDR enabling launches in Germany, Italy, and the U.K.; real-world data showed a 36% reduction in hospital length-of-stay and approximately $42,000 per-patient cost savings versus split-thickness grafts; full-year 2025 revenue guidance was lowered to $70–$74M. The company amended its credit agreement, adding $500,000 to loan principal and resetting a revenue covenant to $70M for Q4 2025.
AVITA Medical (NASDAQ: RCEL) presented two studies at the 2025 Southern Region Burn Conference reinforcing the RECELL System as a standard of care in acute wound treatment. A global systematic review of 99 studies (>8,000 patients, 13 countries) found RECELL reduces donor site size (up to 97.55%), achieves rapid wound closure comparable or superior to STSG, and shows favorable pain, aesthetic, and health-economic outcomes. A U.S. registry analysis (ABA Burn Care Quality Platform; >8,500 RECELL patients) reported a 36% shorter hospital stay (5.6 days; p<0.0001), 83% discharged home vs 70% for STSG, and estimated cost savings of >$42,000 per patient.
AVITA Medical (NASDAQ: RCEL) will report third quarter 2025 financial results after U.S. market close on Thursday, November 6, 2025. The company will host a conference call and webcast the same day at 1:30 p.m. Pacific Time (Friday, November 7, 2025 at 8:30 a.m. Australian Eastern Daylight Time) to discuss results and recent business highlights.
The live webcast will be available in the Events & Presentations section of AVITA Medical's investor website at ir.avitamedical.com. Telephone participants must register in advance to receive dial-in details and a personal PIN; a replay will be posted on the investor site shortly after the live event.
AVITA Medical (NASDAQ: RCEL) announced that Australia’s Medical Services Advisory Committee (MSAC) recommended amendments to the Medicare Benefits Schedule to include autologous skin cell suspension (ASCS) prepared with RECELL for severe acute burn wounds in adults and children.
MSAC concluded RECELL is as safe and effective as traditional autologous skin grafting and noted benefits including donor site sparing, reduced need for additional grafting, shorter hospital stays, less pain, and minimized scarring. Recommended uses include adults with ≥20% TBSA, pediatrics with ≥10% TBSA, and whole-of-face closure.
AVITA Medical (NASDAQ: RCEL) announced an immediate CEO transition: Board Chairman Cary Vance is named Interim CEO and will remain Chairman, while former CEO Jim Corbett is leaving the company. Board member Jan Stern Reed was appointed Lead Independent Director and the Board will engage a search firm to find a permanent CEO, considering internal and external candidates including Mr. Vance.
The Company expects preliminary Q3 2025 revenue of approximately $17 million. AVITA secured a waiver from OrbiMed for the Q3 2025 trailing 12-month net revenue covenant and is negotiating revised future covenants. An earnings call is scheduled for November 6, 2025.
FAQ
What is the current stock price of Avita Medical (RCEL)?
What is the market cap of Avita Medical (RCEL)?
